-
Mashup Score: 0Durvalumab + Ceralasertib Treatment in... : Oncology Times - 4 day(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Durvalumab + Ceralasertib Treatment in... : Oncology Times - 7 day(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Durvalumab + Ceralasertib Treatment in... : Oncology Times - 12 day(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Durvalumab + Ceralasertib Treatment in... : Oncology Times - 16 day(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Real-world data support the use of crizotinib as standard care for patients with advanced NSCLC with ROS1 fusions, according to researchers.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Durvalumab + Ceralasertib Treatment in... : Oncology Times - 23 day(s) ago
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Leukocyte Count in Robot vs Video Thoracic Surgery As Surgical Stress Indicator - Oncology Nurse Advisor - 30 day(s) ago
Researchers analyzed the surgical stress response and tissue trauma in patients with NSCLC after robot-assisted and video-assisted procedures using leukocyte count as a surrogate measure.
Source: www.oncologynurseadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 31KRAS in NSCLC: Beyond G12C | IASLC - 1 month(s) ago
In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses KRAS mutant non-small cell lung cancer, focusing on non-G12C mutations. KRAS mutations …
Source: www.iaslc.orgCategories: General Medicine News, Onc News and JournalsTweet-
KRAS mutations are common in #lungcancer, & while there are multiple approved/active KRAS inhibitors, they are specifically for the G12C mutation. @StephenVLiu discusses KRAS mutant #NSCLC w/focus on non-G12C mutations w/Dr. Veluswamy & @MarianaBrandao0: https://t.co/iI5ORV5u8l https://t.co/RPxBJbqO5a
-
-
Mashup Score: 1Benefits of Neoadjuvant Chemoimmunotherapy Confirmed in Early NSCLC - 1 month(s) ago
Neoadjuvant chemoimmunotherapy improves outcomes over chemotherapy alone in patients with early-stage NSCLC, according to a meta-analysis.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Alectinib Outperforms Chemo in ALK+ NSCLC - 1 month(s) ago
Adjuvant alectinib improved disease-free survival when compared to platinum-based chemotherapy in patients with ALK-positive non-small cell lung cancer in a phase 3 trial.
Source: www.cancertherapyadvisor.comCategories: General Medicine News, Onc News and JournalsTweet
Results from the Phase II umbrella HUDSON study demonstrated that durvalumab coupled with ceralasertib boosted immune response and improved outcomes among patients with non-small cell #lungcancer. https://t.co/cVytNgQAzp #NSCLC https://t.co/2hiRREwB4V